Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first‐in‐human and first‐in‐patient trials

Itepekimab is a monoclonal antibody that targets interleukin (IL‐33) and has been shown to reduce airway inflammation and associated tissue damage in preclinical studies. We assessed the safety, tolerability, pharmacokinetics (PKs), and pharmacodynamic profiles of single‐ascending and multiple‐ascen...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosloski, Matthew P., Kalliolias, George D., Xu, Christine R., Harel, Sivan, Lai, Ching‐Ha, Zheng, Wenjun, Davis, John D., Kamal, Mohamed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841494/
https://www.ncbi.nlm.nih.gov/pubmed/34523807
http://dx.doi.org/10.1111/cts.13157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841494/
https://www.ncbi.nlm.nih.gov/pubmed/34523807
http://dx.doi.org/10.1111/cts.13157

Ejemplares similares